Brain-computer interface (BCI) developer Synchron has officially opened a patient registry for its upcoming large-scale clinical trial, a pivotal move in the race to bring neural implant technology to the mainstream. The company is developing the Synchron Switch, a device designed to help patients with severe paralysis control computers and smart devices using only their thoughts.
Unlike competitors such as Elon Musk’s Neuralink, which requires drilling into the skull for implantation, Synchron’s device utilizes a minimally invasive endovascular approach. The implant is delivered to the brain’s motor cortex through the jugular vein, avoiding the need for open-brain surgery. This method could potentially offer a safer profile and a more straightforward regulatory pathway.
The launch of the patient registry is a crucial step for Synchron as it prepares for a pivotal FDA-approval study. The company has already demonstrated success in its initial COMMAND human trials, where patients were able to perform tasks like texting, emailing, and online banking. By opening a public registry, Synchron aims to build a large pool of eligible candidates to accelerate the enrollment process for its larger trials.
This development signals a significant maturation of the BCI industry, moving from small-scale feasibility studies to larger, more definitive clinical trials. With backing from high-profile investors and a unique technological approach, Synchron is positioning itself as a formidable player in the field. The success of this next phase of testing could bring life-changing technology a step closer to reality for millions of people affected by paralysis, amyotrophic lateral sclerosis (ALS), and other neurological conditions.
English 
Deutsch